Rotavirus Vaccine
Pre-clinicalUNKNOWN 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Vaccination
Conditions
Vaccination, Rotavirus Infections, Meningococcal Infections
Trial Timeline
May 1, 2022 → Apr 1, 2023
NCT ID
NCT05212935About Rotavirus Vaccine
Rotavirus Vaccine is a pre-clinical stage product being developed by Merck for Vaccination. The current trial status is unknown. This product is registered under clinical trial identifier NCT05212935. Target conditions include Vaccination, Rotavirus Infections, Meningococcal Infections.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05212935 | Pre-clinical | UNKNOWN |
| NCT01195844 | Pre-clinical | Terminated |
Competing Products
6 competing products in Vaccination
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Purified Vi capsular polysaccharide of Salmonella typhi conjugated to tetanus toxoid as carrier protein (Typhoid Vi Conjugate Vaccine I.P.). Trade name: ZyVac® TCV | Zydus Lifesciences | Phase 3 | 77 |
| HPV vaccine | Merck | Pre-clinical | 23 |
| Bretovameran | Pfizer | Pre-clinical | 22 |
| Flublok Quadrivalent vaccine + Fluarix Quadrivalent vaccine + Flucelvax Quadrivalent vaccine | Sanofi | Phase 3 | 76 |
| IMVAMUNE® | Bavarian Nordic | Approved | 82 |
| VIGIV | Emergent BioSolutions | Pre-clinical | 15 |